|
First author, year of publication, and reference
|
Patient country of origin
|
Dominant ethnicity
|
Study design
|
Malignant disease
|
Main type of pathology
|
Detected sample
|
Survival analysis
|
Source of HR
|
Maximum follow-up, months
|
|---|
|
Lee, 2013 [5]
|
USA
|
White
|
R
|
Brain glioma
|
Glioblastoma
|
Tissue
|
OS
|
Reported
|
120
|
|
Saija, 2013 [6]
|
Finland
|
White
|
R
|
Brain glioma
|
Glioblastoma
|
Tissue
|
OS
|
SC
|
135
|
|
Campayo, 2013 [7]
|
Spain
|
White
|
R
|
NSCLC
|
Adeno/SCC
|
Tissue
|
RFS
|
SC
|
36
|
|
Yu, 2013 [11]
|
China
|
Asian
|
R
|
HNC
|
SCC
|
Tissue
|
OS
|
SC
|
60
|
|
Avgeris, 2013 [20]
|
Greece
|
White
|
R
|
Prostate cancer
|
Adeno
|
Tissue
|
DFS
|
Reported
|
72
|
|
Tang, 2013 [21]
|
China
|
Asian
|
R
|
Osteosarcoma
|
Sarcoma
|
Tissue
|
OS/DFS
|
Reported
|
152
|
|
Tanaka, 2013 [22]
|
Japan
|
Asian
|
R
|
Esophageal cancer
|
SCC
|
Serum
|
PFSa
|
SC
|
39
|
|
Speranza, 2012 [23]
|
Italy
|
White
|
R
|
Brain glioma
|
Glioblastoma
|
Tissue
|
OS
|
SC
|
18
|
|
Kang, 2012 [24]
|
Korea
|
Asian
|
R
|
Prostate cancer
|
Adeno
|
Tissue
|
RFS
|
Reported
|
55
|
|
Schee, 2012 [25]
|
Norway
|
White
|
R
|
CRC
|
Adeno
|
Tissue
|
MFS
|
SC
|
60
|
|
Law, 2012 [9]
|
China
|
Asian
|
R
|
HCC
|
Adeno
|
Tissue
|
DFS
|
SC
|
144
|
|
Ko, 2012 [12]
|
Canada
|
White
|
R
|
Esophageal cancer
|
SCC
|
Tissue
|
DFS
|
SC
|
32
|
|
Huang, 2012 [26]
|
China
|
Asian
|
R
|
Cervical cancer
|
Small cell carcinoma
|
Tissue
|
OS
|
SC
|
70
|
|
Marchini, 2011 [27]
|
Italy
|
White
|
R
|
EOC
|
Adeno
|
Tissue
|
OS/PFS
|
Reported
|
143
|
|
Radojicic, 2011 [28]
|
Greece
|
White
|
R
|
Breast cancer
|
Adeno
|
Tissue
|
OS/DFS
|
SC
|
120
|
|
Leite, 2011 [13]
|
Brazil
|
White
|
R
|
Prostate cancer
|
Adeno
|
Tissue
|
RFS
|
Reported
|
122
|
|
Hamano, 2011 [29]
|
Japan
|
Asian
|
R
|
Esophageal cancer
|
SCC
|
Tissue
|
OS
|
SC
|
97
|
|
Drebber, 2011 [30]
|
Germany
|
White
|
R
|
Rectal cancer
|
Adeno
|
Tissue
|
OS
|
SC
|
72
|
- Adeno, adenocarcinoma; CRC, colorectal cancer; DFS, disease-free surviva; EOC, epithelial ovarian cancer; HCC, hepatocellular carcinoma; HNC, head and neck cancer; HR, hazard ratio; MFS, metastasis-free survival; NSCLC, non-small cell lung cancer; OS, overall survival; P, prospective; PFS, progression-free survival; R, retrospective; RCC, renal cell carcinoma; RFS, relapse-free survival; SC, survival curve; SCC, squamous cell carcinoma.
- aPFS included any of the following: DFS, MFS or RFS.
